Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
10 July 2015
E-006876/2015
Answer given by Mr Moedas on behalf of the Commission

1. The Commission is aware of the study referred to by the Honourable Member(1). Research on Alzheimer's disease has been a longstanding priority for the Commission and remains so under Horizon 2020(2), the EU Framework Programme for Research and Innovation (2014-2020). Under Horizon 2020, the Commission offers opportunities for research in this field, including the coordination and alignment of national research efforts through the Joint Programming Initiative on Neurodegenerative Disease Research, in particular Alzheimer's (JPND)(3). Neurodegenerative diseases are also a priority for the Innovative Medicines Initiative 2(4), which has recently launched the IMI Alzheimer's Disease Research Platform(5). As part of the Horizon 2020 2014-2015 calls for proposals, the Commission provided some EUR 25 million to research projects addressing the pathophysiology, treatment and care of Alzheimer's disease and overall EUR 87.5 million for research on dementia.

2. Further opportunities to support research and innovation in the field of Alzheimer's disease under Horizon 2020 would be in the form of grants, granted on the basis of competitive calls for proposals following an independent peer-review evaluation. Such opportunities may notably arise from the societal challenge ‘Health, demographic change and wellbeing’(6), which adopts a patient-centred, challenge-driven and solution-focused approach whereby the scientific community is invited to submit proposals that address pressing health issues such as a better understanding of diseases, the development of preventive approaches, new diagnostic tools or new therapies. More information can be found through the Research and Innovation Participant Portal(7).

(1)Apostolova et al. Neurology, 2015; 84 (7): 729.
(2)Regulation (EU) No 1291/2013 of the European Parliament and the Council of 11.12.2013 establishing Horizon 2020 — the framework Programme for Research and Innovation (2014-2020) and repealing Decision No 1982/2006/EC, OJ L 347, 20.12.2013.
(3)http://www.neurodegenerationresearch.eu/
(4)http://www.imi.europa.eu/content/imi-2
(5)http://www.imi.europa.eu/content/press-release-imi-ad-platform
(6)http://ec.europa.eu/programmes/horizon2020/en/h2020-section/health-demographic-change-and-wellbeing
(7)http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/index.html

Last updated: 3 August 2015Legal notice